ArticlePharmaceutical research2015
Alternating magnetic field-induced hyperthermia increases iron oxide nanoparticle cell association/uptake and flux in blood-brain barrier models.
Article in Pharmaceutical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Review
- Plasma-Nanomedicine Synergistic Therapy for Brain Diseases: Current Status, Applications, and Challenges.Antioxidants (Basel, Switzerland) · 2026Review
- Current advances in metal nanoparticle-based stimuli-responsive nanotherapies.Frontiers in chemistry · 2026Review
- Article
- Review
- Review
- Nanotechnology-based Nose-to-brain Delivery in Epilepsy: A NovelApproach to Diagnosis and Treatment.Pharmaceutical nanotechnology · 2024Review
- Single-domain magnetic particles with motion behavior under electromagnetic AC and DC fields are a fatal cargo in Metropolitan Mexico City pediatric and young adult early Alzheimer, Parkinson, frontotemporal lobar degeneration and amyotrophic lateral sclerosis and in ALS patients.Frontiers in human neuroscience · 2024Article
- Passing of Nanocarriers across the Histohematic Barriers: Current Approaches for Tumor Theranostics.Nanomaterials (Basel, Switzerland) · 2023Review
- Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects.Nanomaterials (Basel, Switzerland) · 2022Review
- Tuning of Magnetic Hyperthermia Response in the Systems Containing Magnetosomes.Molecules (Basel, Switzerland) · 2022Article
- Targeted Delivery Methods for Anticancer Drugs.Cancers · 2022Review
- Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer.Journal of immunology research · 2022Review
- Transportation of Single-Domain Antibodies through the Blood-Brain Barrier.Biomolecules · 2021Review
- Therapeutic response differences between 2D and 3D tumor models of magnetic hyperthermia.Nanoscale advances · 2021Review
- Electromagnetically Stimuli-Responsive Nanoparticles-Based Systems for Biomedical Applications: Recent Advances and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2021Review
- Nano-Neurotheranostics: Impact of Nanoparticles on Neural Dysfunctions and Strategies to Reduce Toxicity for Improved Efficacy.Frontiers in pharmacology · 2021Review
- Microfluidic Synthesis of Iron Oxide Nanoparticles.Nanomaterials (Basel, Switzerland) · 2020Review
- Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.Molecules (Basel, Switzerland) · 2020Review
- Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeSuperparamagnetic iron oxide nanoparticles (IONPs) are being investigated for brain cancer therapy because alternating magnetic field (AMF) activates them to produce hyperthermia. For central nervous system applications, brain entry of diagnostic and therapeutic agents is usually essential. We hypothesized that AMF-induced hyperthermia significantly increases IONP blood-brain barrier (BBB) association/uptake and flux.
methodsCross-linked nanoassemblies loaded with IONPs (CNA-IONPs) and conventional citrate-coated IONPs (citrate-IONPs) were synthesized and characterized in house. CNA-IONP and citrate-IONP BBB cell association/uptake and flux were studied using two BBB Transwell(®) models (bEnd.3 and MDCKII cells) after conventional and AMF-induced hyperthermia exposure.
resultsAMF-induced hyperthermia for 0.5 h did not alter CNA-IONP size but accelerated citrate-IONP agglomeration. AMF-induced hyperthermia for 0.5 h enhanced CNA-IONP and citrate-IONP BBB cell association/uptake. It also enhanced the flux of CNA-IONPs across the two in vitro BBB models compared to conventional hyperthermia and normothermia, in the absence of cell death. Citrate-IONP flux was not observed under these conditions. AMF-induced hyperthermia also significantly enhanced paracellular pathway flux. The mechanism appears to involve more than the increased temperature surrounding the CNA-IONPs.
conclusionsHyperthermia induced by AMF activation of CNA-IONPs has potential to increase the BBB permeability of therapeutics for the diagnosis and therapy of various brain diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.